PT-141 Dosage Guide: Protocols, Timing, and Administration for Men and Women

Understanding Why Dosage Precision Matters

PT-141 (bremelanotide) sits at an unusual intersection: it is both an FDA-approved pharmaceutical (Vyleesi®, approved 2019 for HSDD in premenopausal women) and a widely used off-label compound for men. That dual status creates a fragmented dosing landscape. Approved prescribing information covers one population and one administration route; clinical experience with men, postmenopausal women, and intranasal protocols has accumulated outside the trial framework.

The consequence for patients is that dosing information is often either copy-pasted from the package insert without clinical nuance, or drawn from bodybuilding forums without any pharmacological grounding. This article is an attempt to close that gap — translating the available evidence, and what I discuss with patients when I help them make an informed decision, into a structured reference.

The pharmacology is worth one paragraph before the numbers. PT-141 is a cyclic heptapeptide that acts as an agonist at melanocortin receptors, primarily MC3R and MC4R in the hypothalamus and limbic system. The result is a centrally mediated increase in sexual motivation — desire and arousal — rather than a peripheral vascular effect. Because the mechanism is central, the dose-response curve is steep at the low end: the difference between 0.75 mg and 1.75 mg is clinically meaningful, but going above 1.75 mg does not proportionally increase efficacy while substantially increasing side-effect burden.

HSDD means persistently low sexual desire that causes distress and is not better explained by another medical or psychiatric condition, relationship problems or medication. That diagnostic step matters, because low desire often has a cause that needs a different treatment. Bremelanotide is chemically related to melanotan II, an older and unapproved tanning peptide, but it is a different product with a different safety record.

What the Evidence Shows

The effect is real but modest. Many women in the trials did not respond meaningfully, and the trials enrolled mostly white, US-based, premenopausal women with a mean age of 39 [1]. The phase 3 data do not establish efficacy in men, in postmenopausal women or for intranasal use; the dosing for those groups below reflects off-label practice.

Protocol table: doses at a glance

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Why the trial doses and community doses look so different. The 1.75 mg dose for women came out of a dose-finding trial and was then tested in phase 3. The trials in men were early lab studies; they measured erections with a RigiScan device after single doses of up to 10 mg subcutaneously or above 7 mg intranasally, well above the doses reported in community use. Community practice settles at 0.5-2 mg subcutaneously because nausea climbs with dose. On the label, nausea affected 40% of women on 1.75 mg against 1.3% on placebo, and 8% stopped treatment because of it. The intranasal doses people use from compounded sprays (1-2 mg) are well below the intranasal doses that worked in the trials, which may explain why nasal use is reported as unreliable.

Test dose and titration as it is actually done. People start at 0.5-1.0 mg to see whether they get nausea, then move up in steps of 0.25-0.5 mg on later occasions. Response varies widely: some report a full effect at 0.5 mg, others need 2 mg.

Why the frequency limit matters. In a study cited on the label, 38% of women developed focal skin darkening after 8 consecutive days of daily dosing, compared with 1% in the phase 3 trials at up to 8 doses a month. Daily use is the pattern most likely to cause pigment changes that may not fully fade.

A caution on the sildenafil non-responder trial. It is the only large randomised trial in men (342 men, 10 mg intranasal), but in 2023 the journal published an expression of concern about this paper, and it should be weighed accordingly.

After stopping. PT-141 works dose by dose and nothing builds up. The label advises stopping after 8 weeks if there is no improvement. In the 52-week open-label extension, 684 women entered and 272 completed it (Simon 2019).

Technique, reconstitution and storage are in the peptide injection guide.

Standard Subcutaneous Protocol (Women — FDA-Approved Vyleesi®)

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

The approved Vyleesi protocol is the most evidence-grounded starting point:

Dose: 1.75 mg per use, delivered as a single subcutaneous injection via prefilled auto-injector

Site: Abdomen or thigh; rotate sites with repeated use to minimize local tissue reaction

Timing: Administer at least 45 minutes before anticipated sexual activity. Onset is typically 45–60 minutes; peak central effect is reached at 1–3 hours and can persist for 6–12 hours in some individuals

Frequency: No more than once per 24-hour period; the FDA specifically recommends no more than 8 doses per month. This limit is based on both cardiovascular safety (transient blood pressure elevation occurs with each dose) and hyperpigmentation risk, which increases with cumulative exposure

If the first dose is ineffective: The next attempt may use 1.75 mg again; there is no dose escalation above 1.75 mg sanctioned by the label. If two to three 1.75 mg doses fail to produce any effect, this signals a non-responder rather than a dosing problem, and alternative approaches should be explored.

Titration Strategy to Minimize Nausea

The most common reason patients discontinue PT-141 is nausea, which occurs in approximately 40% of subjects at 1.75 mg in clinical trials. The label notes that it improved for most women with the second dose. Starting low has not been tested in a trial; it is a practice pattern, and community reports describe less nausea at 0.5–1.0 mg (see the protocol table). A typical sequence:

1. Week 1–2: Administer 0.75 mg SC 45–60 minutes before activity. Note response and tolerability.
2. Week 3–4: If 0.75 mg is well-tolerated but effect is insufficient, increase to 1.0–1.25 mg.
3. Week 5+: Titrate to 1.75 mg if needed for adequate effect.

Many patients find 1.0–1.25 mg sufficient for a satisfactory response with significantly lower nausea compared to the full 1.75 mg dose. This represents a real-world optimization that the label does not capture because trials used fixed dosing.

Nausea Mitigation Protocol

For patients who experience nausea even at lower doses:

• Ondansetron taken beforehand does not help. In a placebo-controlled phase 4 study cited on the label, 228 healthy women took 8 mg ondansetron or placebo 30 minutes before 1.75 mg PT-141, and nausea rates did not differ. The label advises against this pre-treatment; ondansetron given after nausea starts has not been studied. In the phase 3 trials, 13% of women needed an anti-emetic.
• Eat a light meal 1–2 hours before dosing and avoid dosing on a completely empty stomach. This is a practical habit; food does not change absorption of a subcutaneous dose.
• Inject slowly. The auto-injector delivers the dose rapidly; in compounded formulations drawn into a syringe, a slower push over 5–10 seconds can reduce immediate nausea.
• Remain upright for at least 20–30 minutes post-injection. Lying flat immediately after dosing correlates with more pronounced nausea.
• Avoid alcohol on dosing days — alcohol potentiates nausea and may exaggerate the transient blood pressure rise.

Off-Label Dosing: Men with Low Desire or Erectile Dysfunction

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

No formal prescribing guidelines exist for men. The available evidence derives from early placebo-controlled single-dose studies in healthy men and men with erectile dysfunction, intranasal (Diamond et al. 2004) [5] and subcutaneous (Rosen et al. 2004) [7], plus community reports and the experience of men’s health physicians. The dosing architecture is similar to women:

Starting dose: 0.5–1.0 mg SC, administered 45–60 minutes before activity

Titration: Increase by 0.25–0.5 mg per attempt as tolerated, targeting the minimum effective dose. Community reports put the effective range at 1.0–2.0 mg, and some men report needing more (Anecdotal; see the protocol table).

Upper end: The label dose for women is 1.75 mg. In the single-dose lab studies, healthy men received up to 10 mg subcutaneously and it was reported as well tolerated [7], but nausea and the blood pressure rise climb with dose, and repeated home use above 2 mg has not been studied.

Frequency: The same ceiling of 8 doses per month is used. On the label it rests on the pigmentation data (1% at up to 8 doses a month, 38% after 8 consecutive daily doses), on the longer time each month with raised blood pressure, and on the fact that few trial participants dosed more often. The label does not cite receptor desensitisation.

In men with mixed desire + erectile dysfunction: PT-141 addresses the central desire component; it does not reliably restore erections in men with vascular or neurogenic ED. In these patients, PT-141 can be combined with a PDE5 inhibitor (sildenafil, tadalafil) — the two mechanisms are complementary and do not pharmacologically conflict. However, the cardiovascular burden of combining PT-141 (transient BP rise) with PDE5 inhibition (vasodilation) warrants caution and patient-specific risk assessment.

Intranasal Protocol: What the Research Shows

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

The original PT-141 development program explored intranasal delivery before pivoting to subcutaneous [5]. Nasal administration is attractive for ease of use but needs much larger doses. In the early lab studies in men, subcutaneous doses above 1 mg produced significant erections [7], while intranasal doses had to exceed 7 mg [5].

Intranasal dosing (off-label, compounded formulations only):

• Trial doses: a significant effect only above 7 mg per dose [5]; 7.5 mg combined with 25 mg sildenafil [8]; 10 mg in the trial in sildenafil non-responders [9]
• Community use of compounded sprays: 1–2 mg per use (Anecdotal), far below the trial doses, which may explain why nasal use is reported as unreliable
• Timing: in the intranasal study, peak blood levels came at about 30 minutes and the first erection at about 30 minutes; half-life was roughly 2 hours [5]
• Nasal irritation is an additional side effect not seen with SC administration

The practical trade-off: intranasal requires a larger dose (higher cost per use) and a compounded formulation. For patients with significant needle aversion, the convenience may justify the added dose and cost. For most patients, subcutaneous administration via a fine insulin-gauge needle (28–31G, 0.5 inch) is well tolerated and more cost-effective.

Specific Population Adjustments

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Postmenopausal Women

PT-141 is not FDA-approved for postmenopausal women, and the phase 3 RECONNECT trials enrolled only premenopausal women [1]. Evidence in postmenopausal women is limited to early-phase data, and the safety review is less complete. In clinical practice, the same 1.75 mg protocol is used, with one important caveat: cardiovascular risk profile should be assessed before starting. Postmenopausal women have higher baseline cardiovascular risk, and PT-141’s transient blood pressure elevation (maximal rises of 6 mmHg systolic and 3 mmHg diastolic on the label) requires that resting BP be well-controlled first.

Older Patients (> 65 Years)

No dose reduction is required based on age alone. However, the cardiovascular caution noted above applies with greater force. Renal and hepatic function should be reviewed — in severe impairment, PT-141 clearance may be delayed, effectively extending the duration of action and side-effect window. A starting dose of 0.75 mg with cautious titration is prudent.

Patients on Antihypertensives

PT-141 transiently raises blood pressure after each dose; on the label the rise peaks 2–4 hours after the dose and is usually gone within 12 hours. This does not mean antihypertensive therapy is a contraindication — in fact, patients with well-controlled hypertension on stable medication are reasonable candidates. The specific concern is patients on medications that make BP labile or who have autonomic dysfunction. Check a resting BP on the day of the first dose; if above 140/90 mmHg, defer until control is improved.

Patients Taking Serotonergic Drugs

PT-141 is metabolized via non-CYP pathways and does not interact with SSRIs or SNRIs at the CYP level. However, serotonergic agents are a frequent cause of sexual dysfunction — which is why some patients seek PT-141 in the first place. There is no documented pharmacodynamic interaction that would make PT-141 dangerous in combination with SSRIs; the two affect different systems (melanocortin vs. serotonin). Clinical monitoring for additive nausea is reasonable.

Cycling and Long-Term Use

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

The label gives its reasons for the limit of 8 doses per month: few trial participants dosed more often, and more frequent dosing raises the pigmentation risk and lengthens the time each month with raised blood pressure.

Receptor desensitisation. This is often given as a reason, but neither the label nor the trials show it. In the 52-week open-label extension, desire and distress scores stayed improved in women who kept using it at up to 8 doses a month [6]. Whether more frequent dosing blunts the response has not been studied.

Hyperpigmentation. PT-141 stimulates MC1R in addition to MC3R/MC4R. MC1R activation drives melanin production, the same pathway behind the tanning effect of melanotan II. The label reports focal hyperpigmentation of the face, gums and breasts in 1% at up to 8 doses a month and in 38% after 8 consecutive daily doses. Darker skin carries a higher risk, and resolution after stopping was not confirmed in all patients. In patients with a personal or family history of melanoma, dermatological monitoring is appropriate with longer-term use.

Some people who use PT-141 over months take planned breaks. This is a practice habit, not a tested protocol:

• Active period: 3 months of use at ≤ 8 doses/month
• Washout period: 4–6 weeks off
• Reassess: Restart at lower dose (0.75–1.0 mg) and retitrate

Monitoring Parameters

Before initiation:

• Resting blood pressure (must be < 140/90 mmHg)
• Cardiovascular risk assessment (especially women > 50, men > 45)
• Skin assessment, especially in darker skin, where the label reports a higher risk (baseline for hyperpigmentation monitoring)

After initiation:

• BP check at first use (in-office or home monitor)
• Skin inspection at quarterly visits for patients using > 4 times/month
• Ask about nausea severity at follow-up — persistent grade 2+ nausea despite mitigation strategies suggests dose reduction rather than discontinuation

Known and Theoretical Risks

• Nausea, flushing and headache were the most common side effects in RECONNECT [1].
• Blood pressure: the prescribing information describes transient increases in blood pressure after each dose; people with uncontrolled hypertension or cardiovascular disease are not candidates.
• Skin darkening: focal hyperpigmentation of the face, gums or breasts can occur, particularly with frequent use, and may not fully resolve.
• Drug interactions: the prescribing information describes reduced absorption of some oral medicines taken around the same time, including oral naltrexone.
• Grey-market melanocortin peptides: melanotan II, the related tanning peptide, is linked in published case reports to melanoma [3] and priapism [4]. The FDA lists published reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism for compounded melanotan II. “Research” bremelanotide is not Vyleesi: content, purity and sterility of grey-market vials are unknown, and mislabelled or substituted products are a real risk with online purchases.

Regulatory Status

• FDA (US): bremelanotide (Vyleesi) is FDA-approved for premenopausal women with acquired, generalised HSDD. It is a prescription medicine; use outside that indication is off-label. Melanotan II, a related tanning peptide, appears on the FDA page of bulk substances that may present significant safety risks in compounding (content current as of 22 April 2026).
• EMA / Germany: bremelanotide is not authorised by the EMA, so it is not an approved medicine in Germany. However it is labelled, a “research use only” vial is not an approved medicine and has not been tested for human use.
• WADA 2026: not named; athletes should confirm status with their anti-doping organisation.

When to Talk to a Physician

Talk to a physician (gynaecologist, urologist, sexual medicine specialist or GP) if low desire is causing you distress. A good assessment looks at hormones, medications (antidepressants, hormonal contraception and others), mood, sleep, pain, relationship factors and other medical conditions. If you are a premenopausal woman in the US with HSDD, your doctor can discuss whether Vyleesi fits and will use the official prescribing information. For men, effective approved treatments exist for erectile dysfunction, and low desire in men warrants its own work-up, including testosterone where indicated.

Seek urgent care for an erection lasting more than four hours, severe headache or chest pain, or a changing mole.

Related Articles

• PT-141 (Bremelanotide) Overview
• Peptide Therapy for Women
• Peptide Safety Overview
• Peptide Injections: Safety Guide